Page last updated: 2024-08-17

quinidine and debrisoquin

quinidine has been researched along with debrisoquin in 38 studies

Research

Studies (38)

Timeframe	Studies, this research(%)	All Research%
pre-1990	12 (31.58)	18.7374
1990's	16 (42.11)	18.2507
2000's	9 (23.68)	29.6817
2010's	1 (2.63)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Commandeur, JN; Funae, Y; Hiroi, T; ter Laak, AM; Venhorst, J; Vermeulen, NP	1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM	1
García-Mera, X; González-Díaz, H; Prado-Prado, FJ	1
Araki, J; Masubuchi, Y; Narimatsu, S; Suzuki, T	1
Bélanger, PM; Eichelbaum, M; Fiset, C; Giguère, R; Gilbert, M; Grech-Bélanger, O; Kroemer, HK; Moerike, K; Rouleau, JR; Turgeon, J	1
Ayesh, R; Cholerton, S; Dawling, S; Hayler, A; Idle, JR; Oates, NS; Smith, RL; Widdop, B	1
Broly, F; Caron, J; Lhermitte, M; Libersa, C; Vandamme, N	1
Brøsen, K; Gram, LF; Kragh-Sørensen, P	1
Brøsen, K; Meyer, UA; Zeugin, T	1
Anthony, LB; Roden, DM; Wood, AJ; Zhou, HH	1
Gonzalez, FJ; Hardwick, JP; Inaba, T; Kalow, W; Tyndale, RF	1
Funck-Brentano, C; Roden, DM; Turgeon, J; Woosley, RL	1
Agron, L; Bigot, MC; Camsonne, R; Dao, MT; Debruyne, D; Gram, LF; Grollier, G; Lacotte, J; Moulin, M	1
Dahlqvist, R; Dumont, E; Spina, E; Steiner, E	1
Boobis, AR; Davies, DS; Kobayashi, S; Murray, S; Sesardic, D; Watson, D	1
Hawes, EM; Inaba, T; McKay, G; Midha, KK; Muralidharan, G	1
Crewe, HK; Lennard, MS; Otton, SV; Tucker, GT; Woods, HF	1
Boobis, AR; Davies, DS; Murray, S; Seddon, CE; Speirs, CJ	1
Bertilsson, L; Brøsen, K; Gram, LF; Haghfelt, T	1
Dayer, P; Eichelbaum, M; Kronbach, T; Meyer, UA	1
Dayer, P; Leemann, T; Meyer, UA	1
Inaba, T; Mahon, WA; Tyndale, RE	1
Almeyda, J; Levantine, A	1
Huang, Y; Masubuchi, Y; Mizukami, T; Narimatsu, S; Suzuki, T	2
Bertilsson, L; Dahl, ML; Eichelbaum, M; Ingelman-Sundberg, M; Johansson, I; Meese, CO; Säwe, J; Yue, QY	1
Dayer, P; Devi, KP; Leemann, TD	1
Ebner, T; Eichelbaum, M	1
Cooper, JK; Hawes, EM; Korchinski, ED; Midha, KK; Muralidharan, G	1
Caraco, Y; Sheller, J; Wood, AJ	2
Blackburn, MG; Ellis, SW; Harlow, J; Hayhurst, GP; Larsson, C; Lennard, MS; Lightfoot, T; Lim, CK; Mahling, J; Rowland-Yeo, K; Smith, G; Tucker, GT; Wolf, CR	1
Andersson, K; Bertilsson, L; Dahl, M; Dalén, P	1
Chiba, M; Lin, JH; Lin, Y; Neway, W; Nishime, JA	1
Adedoyin, A; Branch, RA; Frye, RF; Romkes, M; Wilson, JW	1
Gelboin, HV; Gonzalez, FJ; Granvil, CP; Idle, JR; Krausz, KW	1
Katoh, M; Nakajima, M; Sawada, T; Soeno, Y; Tateno, C; Yokoi, T; Yoshizato, K	1
Guo, B; He, MM; Li, C; Liu, H; Shen, H; Wang, L; Wrighton, SA	1

Reviews

2 review(s) available for quinidine and debrisoquin

Article	Year
Inhibition of desipramine 2-hydroxylation by quinidine and quinine in rapid and slow debrisoquine hydroxylators. Psychopharmacology series, 1989, Volume: 7 Topics: Debrisoquin; Depression, Chemical; Desipramine; Humans; Hydroxylation; Isoquinolines; Phenotype; Quinidine; Quinine	1989
Cutaneous reactions to cardiovascular drugs. The British journal of dermatology, 1973, Volume: 88, Issue:3 Topics: Adrenergic beta-Antagonists; Cardiovascular Diseases; Clonidine; Debrisoquin; Digitalis Glycosides; Drug Eruptions; Ethacrynic Acid; Furosemide; Guanethidine; Humans; Hydralazine; Mercury; Methyldopa; Nitroglycerin; Pentaerythritol Tetranitrate; Procainamide; Quinidine; Thiazines	1973

Trials

5 trial(s) available for quinidine and debrisoquin

Article	Year
Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. The Journal of pharmacology and experimental therapeutics, 1989, Volume: 249, Issue:1 Topics: Adult; Anilides; Biological Availability; Debrisoquin; Drug Interactions; Electrocardiography; Encainide; Humans; Male; Metabolic Clearance Rate; Middle Aged; Polymorphism, Genetic; Quinidine	1989
Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine. European journal of clinical pharmacology, 1996, Volume: 50, Issue:1-2 Topics: Adult; Antipsychotic Agents; Chlorpromazine; Chromatography, High Pressure Liquid; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Debrisoquin; Depression, Chemical; Enzyme Inhibitors; Humans; Hydroxylation; Male; Mixed Function Oxygenases; Oxidation-Reduction; Phenotype; Polymorphism, Genetic; Quinidine	1996
Pharmacogenetic determination of the effects of codeine and prediction of drug interactions. The Journal of pharmacology and experimental therapeutics, 1996, Volume: 278, Issue:3 Topics: Adult; Codeine; Cross-Over Studies; Cytochrome P-450 CYP2D6 Inhibitors; Debrisoquin; Double-Blind Method; Drug Interactions; Humans; Male; Pupil; Quinidine; Reflex, Pupillary; Respiration	1996
Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. The Journal of pharmacology and experimental therapeutics, 1999, Volume: 290, Issue:1 Topics: Adult; Analgesics, Opioid; Asian People; Biotransformation; Codeine; Cross-Over Studies; Dealkylation; Debrisoquin; Double-Blind Method; Drug Interactions; Enzyme Inhibitors; Female; Humans; Male; Morphine; Psychomotor Performance; Pupil; Quinidine; Respiratory Mechanics; White People	1999
Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes. British journal of clinical pharmacology, 2000, Volume: 49, Issue:2 Topics: Administration, Oral; Adult; Alleles; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Debrisoquin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gene Dosage; Genotype; Humans; Hydroxylation; Male; Quinidine	2000

Other Studies

31 other study(ies) available for quinidine and debrisoquin

Article	Year
Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities. Journal of medicinal chemistry, 2003, Jan-02, Volume: 46, Issue:1 Topics: Alcohol Oxidoreductases; Amino Acid Sequence; Animals; Aryl Hydrocarbon Hydroxylases; Binding Sites; Coumarins; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 2; Enzyme Inhibitors; Humans; Isoenzymes; Kinetics; Ligands; Mixed Function Oxygenases; Models, Molecular; Molecular Sequence Data; Protein Binding; Quinidine; Quinine; Rabbits; Rats; Sequence Homology, Amino Acid; Sparteine; Species Specificity	2003
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3 Topics:	2008
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species. Bioorganic & medicinal chemistry, 2010, Mar-15, Volume: 18, Issue:6 Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics	2010
Metabolic activation of lidocaine and covalent binding to rat liver microsomal protein. Biochemical pharmacology, 1992, Jun-23, Volume: 43, Issue:12 Topics: Animals; Biotransformation; Carbon Monoxide; Cysteine; Cytochrome P-450 Enzyme System; Debrisoquin; Dose-Response Relationship, Drug; Female; Glutathione; Lidocaine; Male; Microsomes, Liver; NADP; Oxygen; Proadifen; Propranolol; Proteins; Quinidine; Rats; Rats, Inbred Strains	1992
Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. The Journal of pharmacology and experimental therapeutics, 1991, Volume: 259, Issue:2 Topics: Administration, Oral; Adult; Debrisoquin; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Male; Phenotype; Polymorphism, Genetic; Quinidine	1991
Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers. Chirality, 1991, Volume: 3, Issue:1 Topics: Adult; Debrisoquin; Desipramine; Female; Humans; Male; Metabolic Clearance Rate; Molecular Structure; Nortriptyline; Phenotype; Quinidine; Quinine; Reference Values; Stereoisomerism	1991
Single-dose quinidine treatment inhibits mexiletine oxidation in extensive metabolizers of debrisoquine. Life sciences, 1991, Volume: 48, Issue:26 Topics: Debrisoquin; Drug Antagonism; Humans; Metabolic Clearance Rate; Mexiletine; Oxidation-Reduction; Quinidine	1991
Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin. Therapeutic drug monitoring, 1991, Volume: 13, Issue:2 Topics: Administration, Oral; Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Chromatography, Thin Layer; Debrisoquin; Desipramine; Drug Interactions; Humans; Imipramine; Male; Mephenytoin; Phenotype; Quinidine; Sparteine	1991
Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. Clinical pharmacology and therapeutics, 1991, Volume: 49, Issue:6 Topics: Antibodies; Cells, Cultured; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Debrisoquin; DNA; Humans; Imipramine; Isoenzymes; Kidney; Kinetics; Methotrimeprazine; Microsomes, Liver; Mixed Function Oxygenases; Oxidation-Reduction; Polymorphism, Genetic; Quinidine; Sparteine; Transfection	1991
Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. Clinical pharmacology and therapeutics, 1990, Volume: 47, Issue:6 Topics: Adult; Analysis of Variance; Debrisoquin; Drug Interactions; Electrocardiography; Humans; Hydroxylation; Male; Metabolic Clearance Rate; Propranolol; Quinidine; Stereoisomerism	1990
Sparteine metabolism capacity in human liver: structural variants of human P450IID6 as assessed by immunochemistry. Pharmacology & toxicology, 1990, Volume: 67, Issue:1 Topics: Animals; Blotting, Western; Cytochrome P-450 Enzyme System; Debrisoquin; Ethanolamines; Humans; Immunochemistry; In Vitro Techniques; Kinetics; Liver; Quinidine; Rats; Rats, Inbred Strains; Sparteine	1990
Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. International journal of clinical pharmacology research, 1989, Volume: 9, Issue:5 Topics: Adult; Aged; Alcoholism; Antipyrine; Chromatography, Liquid; Debrisoquin; Female; Half-Life; Humans; Isoquinolines; Liver Cirrhosis, Alcoholic; Male; Middle Aged; Quinidine	1989
The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man. Biochemical pharmacology, 1989, Sep-01, Volume: 38, Issue:17 Topics: Animals; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitors; Debrisoquin; Humans; In Vitro Techniques; Liver; Male; Mixed Function Oxygenases; Quinidine; Quinine; Rats; Rats, Inbred Strains; Species Specificity	1989
Selective in vivo inhibition by quinidine of methoxyphenamine oxidation in rat models of human debrisoquine polymorphism. Xenobiotica; the fate of foreign compounds in biological systems, 1989, Volume: 19, Issue:2 Topics: Amphetamines; Animals; Debrisoquin; Female; Humans; Isoquinolines; Methamphetamine; Polymorphism, Genetic; Quinidine; Rats; Rats, Inbred Lew; Rats, Inbred Strains	1989
Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. The Journal of pharmacology and experimental therapeutics, 1988, Volume: 247, Issue:1 Topics: Cytochrome P-450 Enzyme System; Dealkylation; Debrisoquin; Humans; Hydroxylation; In Vitro Techniques; Isoquinolines; Kinetics; Metoprolol; Microsomes, Liver; Quinidine; Quinine; Sparteine	1988
Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. British journal of clinical pharmacology, 1986, Volume: 22, Issue:6 Topics: Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Debrisoquin; Female; Humans; In Vitro Techniques; Isoenzymes; Isoquinolines; Male; Microsomes, Liver; Mixed Function Oxygenases; Oxidoreductases; Phenotype; Quinidine; Quinine	1986
Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. Pharmacology & toxicology, 1987, Volume: 60, Issue:4 Topics: Aged; Debrisoquin; Depression, Chemical; Humans; Hydroxylation; Isoquinolines; Male; Middle Aged; Phenotype; Quinidine	1987
Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency. Biochemical pharmacology, 1987, Dec-01, Volume: 36, Issue:23 Topics: Adult; Aged; Binding, Competitive; Cytochrome P-450 Enzyme System; Debrisoquin; Ethanolamines; Humans; Hydroxylation; Isoenzymes; Isoquinolines; Kinetics; Microsomes, Liver; Middle Aged; Phenotype; Polymorphism, Genetic; Quinidine; Sparteine	1987
Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers. European journal of clinical pharmacology, 1986, Volume: 29, Issue:6 Topics: Adult; Debrisoquin; Depression, Chemical; Humans; Metoprolol; Oxidation-Reduction; Quinidine; Stereoisomerism	1986
Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo. British journal of clinical pharmacology, 1986, Volume: 22, Issue:2 Topics: Adult; Cytochrome P-450 Enzyme System; Debrisoquin; Female; Humans; Isoquinolines; Male; Middle Aged; Oxidation-Reduction; Quinidine; Sparteine	1986
Development of a high-performance liquid chromatographic method for the analysis of enatiomer/enantiomer interaction in oxidative metabolism of bunitrolol in rat liver microsomes. Analytical biochemistry, 1994, Volume: 222, Issue:1 Topics: Adrenergic beta-Antagonists; Animals; Chromatography, High Pressure Liquid; Debrisoquin; Gas Chromatography-Mass Spectrometry; Male; Microsomes, Liver; Oxidation-Reduction; Propanolamines; Quinidine; Quinine; Rats; Rats, Wistar; Stereoisomerism	1994
Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes. Pharmacogenetics, 1993, Volume: 3, Issue:2 Topics: Asian People; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Debrisoquin; Genotype; Haplotypes; Humans; Hydroxylation; Metabolic Clearance Rate; Mixed Function Oxygenases; Polymorphism, Restriction Fragment Length; Quinidine; Stereoisomerism; White People	1993
Similar effect of oxidation deficiency (debrisoquine polymorphism) and quinidine on the apparent volume of distribution of (+/-)-metoprolol. European journal of clinical pharmacology, 1993, Volume: 45, Issue:1 Topics: Adult; Blood Proteins; Debrisoquin; Drug Interactions; Humans; Male; Metoprolol; Phenotype; Polymorphism, Genetic; Protein Binding; Quinidine	1993
The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism. British journal of clinical pharmacology, 1993, Volume: 35, Issue:4 Topics: Aprindine; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Debrisoquin; Humans; Hydroxylation; Kinetics; Microsomes, Liver; Mixed Function Oxygenases; Polymorphism, Genetic; Propafenone; Quinidine; Sparteine	1993
In-vitro metabolic interaction of bunitrolol enantiomers in rabbit liver microsomes. The Journal of pharmacy and pharmacology, 1996, Volume: 48, Issue:11 Topics: Adrenergic beta-Antagonists; Animals; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Debrisoquin; Female; Hydroxylation; In Vitro Techniques; Kinetics; Male; Microsomes, Liver; Propanolamines; Quinidine; Quinine; Rabbits; Rats; Rats, Wistar; Species Specificity; Stereoisomerism	1996
Evidence that serine 304 is not a key ligand-binding residue in the active site of cytochrome P450 2D6. The Biochemical journal, 2000, Feb-01, Volume: 345 Pt 3 Topics: Alanine; Amino Acid Substitution; Aspartic Acid; Binding Sites; Catalytic Domain; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Debrisoquin; Enzyme Inhibitors; Kinetics; Ligands; Metoprolol; Mutagenesis, Site-Directed; Oxidation-Reduction; Propranolol; Quinidine; Quinine; Serine; Substrate Specificity; Yeasts	2000
Comparative in vitro metabolism of indinavir in primates--a unique stereoselective hydroxylation in monkey. Xenobiotica; the fate of foreign compounds in biological systems, 2000, Volume: 30, Issue:2 Topics: Animals; Antibodies, Monoclonal; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Debrisoquin; HIV Protease Inhibitors; Humans; Hydroxylation; Indinavir; Kinetics; Microsomes, Liver; Mixed Function Oxygenases; Molecular Conformation; Molecular Structure; Primates; Quinidine; Quinine	2000
In vivo modulation of CYP enzymes by quinidine and rifampin. Clinical pharmacology and therapeutics, 2000, Volume: 68, Issue:4 Topics: Acetylation; Administration, Oral; Adrenergic alpha-Antagonists; Adult; Anti-Arrhythmia Agents; Antibiotics, Antitubercular; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Caffeine; Central Nervous System Stimulants; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dapsone; Debrisoquin; Drug Administration Schedule; Enzyme Inhibitors; Humans; Male; Mephenytoin; Mixed Function Oxygenases; Quinidine; Reference Values; Rifampin; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Theophylline	2000
4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine. The Journal of pharmacology and experimental therapeutics, 2002, Volume: 301, Issue:3 Topics: Adrenergic Agents; Antimalarials; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Debrisoquin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Hydroxylation; Microsomes; Quinidine; Quinine	2002
In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver. Journal of pharmaceutical sciences, 2007, Volume: 96, Issue:2 Topics: Adrenergic Agents; Animals; Chimera; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Debrisoquin; Drug Interactions; Humans; Infant; Liver; Male; Mice; Mice, SCID; Models, Animal; Paroxetine; Quinidine; Urokinase-Type Plasminogen Activator	2007
Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug metabolism and disposition: the biological fate of chemicals, 2007, Volume: 35, Issue:8 Topics: Atomoxetine Hydrochloride; Cocaine; Codeine; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Debrisoquin; Dextromethorphan; Enzyme Inhibitors; Ethanolamines; Fluoxetine; Humans; Hydroxylation; Imipramine; Kinetics; Microsomes; Molecular Structure; Nortriptyline; Polymorphism, Single Nucleotide; Propylamines; Quinidine; Recombinant Proteins; Thioridazine; Tramadol	2007